TGFB1 and neoplasm: Tranilast micelles were found to inhibit pro-tumor immunosuppressive signaling and increase T cell infiltration in immune “cold” solid tumors, indicating that TGF-β targeting is a promising strategy for overcoming immune checkpoint blockade therapy resistance.